Technical Analysis for KALV - KalVista Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 16.37 1.61% 0.26
KALV closed up 1.61 percent on Friday, August 16, 2019, on 28 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical KALV trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
20 DMA Resistance Bearish 1.61%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.61%
Outside Day Range Expansion 1.61%
Fell Below 20 DMA Bearish 1.36%
Inside Day Range Contraction 1.36%
Slingshot Bearish Bearish Swing Setup -2.68%
Crossed Above 20 DMA Bullish -2.68%

Older signals for KALV ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Medical Specialties Pharmaceutical Diseases Organ Systems Enzymes Diabetic Macular Edema Hereditary Angioedema Angioedema Protease Inhibitor
Is KALV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 34.92
52 Week Low 13.1
Average Volume 176,874
200-Day Moving Average 21.2266
50-Day Moving Average 18.3408
20-Day Moving Average 16.5385
10-Day Moving Average 15.944
Average True Range 0.9122
ADX 23.96
+DI 15.8127
-DI 23.3874
Chandelier Exit (Long, 3 ATRs ) 16.1534
Chandelier Exit (Short, 3 ATRs ) 17.7666
Upper Bollinger Band 18.2022
Lower Bollinger Band 14.8748
Percent B (%b) 0.45
BandWidth 20.119116
MACD Line -0.6762
MACD Signal Line -0.8348
MACD Histogram 0.1586
Fundamentals Value
Market Cap 159 Million
Num Shares 9.71 Million
EPS -3.07
Price-to-Earnings (P/E) Ratio -5.33
Price-to-Sales 202.03
Price-to-Book 4.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.33
Resistance 3 (R3) 17.28 16.92 17.17
Resistance 2 (R2) 16.92 16.67 16.94 17.12
Resistance 1 (R1) 16.64 16.52 16.78 16.69 17.06
Pivot Point 16.28 16.28 16.35 16.30 16.28
Support 1 (S1) 16.00 16.03 16.14 16.05 15.68
Support 2 (S2) 15.64 15.88 15.66 15.62
Support 3 (S3) 15.36 15.64 15.57
Support 4 (S4) 15.41